An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, tiragolumab and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

This study is a pioneering effort to explore a new treatment approach for advanced cancers. When cancer spreads from where it started to other parts of the body, it's called metastatic cancer. This study is focusing on several types of metastatic cancer, including lung, kidney, bladder, and head and neck cancers. The treatment being tested is a combination of two immunotherapy drugs, atezolizumab and tiragolumab, alongside a targeted radiation treatment called stereotactic body radiation therapy (SBRT). Immunotherapy drugs help your body's immune system recognize and fight cancer cells more effectively, while SBRT uses high doses of radiation aimed very precisely at tumors to destroy them.

The main purpose of this early-stage study (called a Phase I study) is to carefully check if this new combination of treatments is safe for people. Safety is always the top priority in new drug research. Researchers will also be looking to see if the treatment shows any signs of being effective in shrinking or controlling the cancer. Even though there's no brief summary provided, the detailed description of a Phase I study means they will start with a small group of patients and gradually increase the dose or adjust the treatment as they learn more about its safety.

Finding new and better ways to treat advanced cancers is very important. By combining different types of treatments like these immunotherapies and targeted radiation, doctors hope to create a stronger attack against cancer while also being as gentle as possible on the rest of the body. This study is a crucial step in understanding whether this particular combination could become a valuable future treatment option for patients.